{"transactions":[{"id":4699,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-04T21:00:25.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":94200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest and become exercisable in fifty equal monthly tranches beginning on the date of grant."}],"balance_after":94200,"derivative":{"exercise_price":1,"expiration_date":"2036-09-02","underlying":"Common Stock","underlying_shares":94200},"source":{"system":"sec-edgar","filing":"0001213900-26-097740","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026097740/ownership.xml","form_type":"4"}},{"id":4698,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-04T21:00:25.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":62800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\"). The RSUs vest as follows: 1/3 on the first anniversary of the date of grant, 1/3 on the second anniversary of the date of grant and 1/3 on the third anniversary of the date of grant."}],"balance_after":63116,"source":{"system":"sec-edgar","filing":"0001213900-26-097740","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026097740/ownership.xml","form_type":"4"}},{"id":733825,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-06-18T00:00:47.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":false,"shares":35,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":212,"derivative":{"underlying":"Common Stock","underlying_shares":35},"source":{"system":"sec-edgar","filing":"0001104659-26-075301","document":"tm2618120-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465926075301/tm2618120-3_4seq1.xml","form_type":"4"}},{"id":733824,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-18T00:00:47.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":true,"shares":35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":26335,"source":{"system":"sec-edgar","filing":"0001104659-26-075301","document":"tm2618120-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465926075301/tm2618120-3_4seq1.xml","form_type":"4"}},{"id":765682,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-05-22T23:01:40.000Z","date":"2026-05-04","kind":"exercise","planned":true,"acquired":false,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":52500,"derivative":{"underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001104659-26-065838","document":"tm2615413-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465926065838/tm2615413-2_4seq1.xml","form_type":"4"}},{"id":765681,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-22T23:01:40.000Z","date":"2026-05-20","kind":"sale","planned":true,"acquired":false,"shares":6845,"price":1.085,"value":7426.825,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 3, 2026 solely to cover taxes due in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $1.07 to $1.105. The Reporting Person undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":26300,"source":{"system":"sec-edgar","filing":"0001104659-26-065838","document":"tm2615413-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465926065838/tm2615413-2_4seq1.xml","form_type":"4"}},{"id":765680,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-22T23:01:40.000Z","date":"2026-05-04","kind":"exercise","planned":true,"acquired":true,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":33145,"source":{"system":"sec-edgar","filing":"0001104659-26-065838","document":"tm2615413-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465926065838/tm2615413-2_4seq1.xml","form_type":"4"}},{"id":778914,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-14T22:32:29.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on the first anniversary of May 12, 2026."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001193125-26-224521","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526224521/ownership.xml","form_type":"4"}},{"id":788407,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-05-07T23:01:04.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":false,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001104659-26-057366","document":"tm2613630-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465926057366/tm2613630-3_4seq1.xml","form_type":"4"}},{"id":788406,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-07T23:01:04.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":true,"shares":9000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":15645,"source":{"system":"sec-edgar","filing":"0001104659-26-057366","document":"tm2613630-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465926057366/tm2613630-3_4seq1.xml","form_type":"4"}},{"id":841409,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-17T00:04:36.000Z","date":"2026-03-15","kind":"exercise","planned":false,"acquired":false,"shares":35,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":247,"derivative":{"underlying":"Common Stock","underlying_shares":35},"source":{"system":"sec-edgar","filing":"0001104659-26-028721","document":"tm268882-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465926028721/tm268882-3_4seq1.xml","form_type":"4"}},{"id":841408,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-17T00:04:36.000Z","date":"2026-03-14","kind":"exercise","planned":false,"acquired":false,"shares":33,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":97,"derivative":{"underlying":"Common Stock","underlying_shares":33},"source":{"system":"sec-edgar","filing":"0001104659-26-028721","document":"tm268882-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465926028721/tm268882-3_4seq1.xml","form_type":"4"}},{"id":841407,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-17T00:04:36.000Z","date":"2026-03-15","kind":"exercise","planned":false,"acquired":true,"shares":35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6645,"source":{"system":"sec-edgar","filing":"0001104659-26-028721","document":"tm268882-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465926028721/tm268882-3_4seq1.xml","form_type":"4"}},{"id":841406,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-17T00:04:36.000Z","date":"2026-03-14","kind":"exercise","planned":false,"acquired":true,"shares":33,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6610,"source":{"system":"sec-edgar","filing":"0001104659-26-028721","document":"tm268882-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465926028721/tm268882-3_4seq1.xml","form_type":"4"}},{"id":950761,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-06T01:01:25.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":70282,"derivative":{"underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001104659-26-000837","document":"tm261931-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465926000837/tm261931-3_4seq1.xml","form_type":"4"}},{"id":969197,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-12-16T01:01:59.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":false,"shares":35,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":282,"derivative":{"underlying":"Common Stock","underlying_shares":35},"source":{"system":"sec-edgar","filing":"0001104659-25-121303","document":"tm2533410-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925121303/tm2533410-3_4seq1.xml","form_type":"4"}},{"id":969196,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-12-16T01:01:59.000Z","date":"2025-12-14","kind":"exercise","planned":false,"acquired":false,"shares":33,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":130,"derivative":{"underlying":"Common Stock","underlying_shares":33},"source":{"system":"sec-edgar","filing":"0001104659-25-121303","document":"tm2533410-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925121303/tm2533410-3_4seq1.xml","form_type":"4"}},{"id":969195,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-16T01:01:59.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":true,"shares":35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6577,"source":{"system":"sec-edgar","filing":"0001104659-25-121303","document":"tm2533410-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925121303/tm2533410-3_4seq1.xml","form_type":"4"}},{"id":969194,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-16T01:01:59.000Z","date":"2025-12-14","kind":"exercise","planned":false,"acquired":true,"shares":33,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6542,"source":{"system":"sec-edgar","filing":"0001104659-25-121303","document":"tm2533410-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925121303/tm2533410-3_4seq1.xml","form_type":"4"}},{"id":1039230,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-09-16T23:04:35.000Z","date":"2025-09-15","kind":"exercise","planned":false,"acquired":false,"shares":35,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":317,"derivative":{"underlying":"Common Stock","underlying_shares":35},"source":{"system":"sec-edgar","filing":"0001104659-25-090517","document":"tm2526247-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925090517/tm2526247-3_4seq1.xml","form_type":"4"}},{"id":1039229,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-09-16T23:04:35.000Z","date":"2025-09-14","kind":"exercise","planned":false,"acquired":false,"shares":33,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":163,"derivative":{"underlying":"Common Stock","underlying_shares":33},"source":{"system":"sec-edgar","filing":"0001104659-25-090517","document":"tm2526247-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925090517/tm2526247-3_4seq1.xml","form_type":"4"}},{"id":1039228,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-09-16T23:04:35.000Z","date":"2025-09-15","kind":"exercise","planned":false,"acquired":true,"shares":35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6509,"source":{"system":"sec-edgar","filing":"0001104659-25-090517","document":"tm2526247-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925090517/tm2526247-3_4seq1.xml","form_type":"4"}},{"id":1039227,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-09-16T23:04:35.000Z","date":"2025-09-14","kind":"exercise","planned":false,"acquired":true,"shares":33,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6474,"source":{"system":"sec-edgar","filing":"0001104659-25-090517","document":"tm2526247-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925090517/tm2526247-3_4seq1.xml","form_type":"4"}},{"id":1074335,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-08-06T00:02:09.000Z","date":"2025-08-01","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."}],"balance_after":9000,"derivative":{"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001104659-25-074372","document":"tm2522669-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925074372/tm2522669-4_4seq1.xml","form_type":"4"}},{"id":1083299,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-07-23T00:26:36.000Z","date":"2025-07-22","kind":"exercise","planned":false,"acquired":false,"shares":625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On July 22, 2024, the Reporting Person was granted 625 RSUs, which vested as to 100% of the total number of RSUs on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On July 22, 2024, the Reporting Person was granted 625 RSUs, which vested as to 100% of the total number of RSUs on the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":625},"source":{"system":"sec-edgar","filing":"0001104659-25-069701","document":"tm2521458-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925069701/tm2521458-2_4seq1.xml","form_type":"4"}},{"id":1083298,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-07-23T00:26:36.000Z","date":"2025-07-22","kind":"exercise","planned":false,"acquired":true,"shares":625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6441,"source":{"system":"sec-edgar","filing":"0001104659-25-069701","document":"tm2521458-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925069701/tm2521458-2_4seq1.xml","form_type":"4"}},{"id":1083297,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-07-23T00:26:36.000Z","date":"2025-07-22","kind":"grant","planned":false,"acquired":true,"shares":4375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer previously granted the Reporting Person an award of restricted stock units that would vest based on the Issuer's satisfaction of certain performance objectives and subject to the Reporting Person's continued service with the Issuer through July 22, 2025 (the \"PSUs\"). On July 22, 2025, the Compensation Committee of the Issuer's Board of Directors determined that performance conditions with respect to 4,375 PSUs had been satisfied and 4,375 shares of common stock became issuable to the Reporting Person on July 22, 2025."}],"balance_after":5816,"source":{"system":"sec-edgar","filing":"0001104659-25-069701","document":"tm2521458-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925069701/tm2521458-2_4seq1.xml","form_type":"4"}},{"id":1109666,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-06-16T23:03:05.000Z","date":"2025-06-15","kind":"exercise","planned":false,"acquired":false,"shares":35,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":352,"derivative":{"underlying":"Common Stock","underlying_shares":35},"source":{"system":"sec-edgar","filing":"0001104659-25-059982","document":"tm2518140-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925059982/tm2518140-4_4seq1.xml","form_type":"4"}},{"id":1109665,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-06-16T23:03:05.000Z","date":"2025-06-14","kind":"exercise","planned":false,"acquired":false,"shares":33,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":196,"derivative":{"underlying":"Common Stock","underlying_shares":33},"source":{"system":"sec-edgar","filing":"0001104659-25-059982","document":"tm2518140-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925059982/tm2518140-4_4seq1.xml","form_type":"4"}},{"id":1109664,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-06-16T23:03:05.000Z","date":"2025-06-15","kind":"exercise","planned":false,"acquired":true,"shares":35,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":1441,"source":{"system":"sec-edgar","filing":"0001104659-25-059982","document":"tm2518140-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925059982/tm2518140-4_4seq1.xml","form_type":"4"}},{"id":1109663,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-06-16T23:03:05.000Z","date":"2025-06-14","kind":"exercise","planned":false,"acquired":true,"shares":33,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":1406,"source":{"system":"sec-edgar","filing":"0001104659-25-059982","document":"tm2518140-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925059982/tm2518140-4_4seq1.xml","form_type":"4"}},{"id":1145295,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-16T20:05:09.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest on a quarterly basis over 12 months following May 15, 2025, subject to the Reporting Person's continued service through each applicable vesting date. The options were issued on May 15, 2025 with an exercise price of $0.99, representing the closing stock price on May 15, 2025."}],"balance_after":125000,"derivative":{"exercise_price":0.99,"expiration_date":"2035-05-15","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0000950170-25-073513","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000095017025073513/ownership.xml","form_type":"4"}},{"id":1183006,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:22:33.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":70311,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":5,"expiration_date":"2033-12-28","underlying":"Common Stock","underlying_shares":70311},"source":{"system":"sec-edgar","filing":"0001213900-25-028232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000121390025028232/ownership.xml","form_type":"4"}},{"id":1183005,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:22:33.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":72156,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":4.96,"expiration_date":"2032-07-01","underlying":"Common Stock","underlying_shares":72156},"source":{"system":"sec-edgar","filing":"0001213900-25-028232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000121390025028232/ownership.xml","form_type":"4"}},{"id":1183004,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:22:33.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18351,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":6.07,"expiration_date":"2031-09-01","underlying":"Common Stock","underlying_shares":18351},"source":{"system":"sec-edgar","filing":"0001213900-25-028232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000121390025028232/ownership.xml","form_type":"4"}},{"id":1183003,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:22:33.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":9.55,"expiration_date":"2030-08-12","underlying":"Common Stock","underlying_shares":8333},"source":{"system":"sec-edgar","filing":"0001213900-25-028232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000121390025028232/ownership.xml","form_type":"4"}},{"id":1183002,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:22:33.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":6.96,"expiration_date":"2029-07-12","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001213900-25-028232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000121390025028232/ownership.xml","form_type":"4"}},{"id":1183001,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:22:33.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":23.49,"expiration_date":"2028-07-13","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001213900-25-028232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000121390025028232/ownership.xml","form_type":"4"}},{"id":1183000,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:22:33.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":41.7,"expiration_date":"2027-03-14","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001213900-25-028232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000121390025028232/ownership.xml","form_type":"4"}},{"id":1182999,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:22:33.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":59.7,"expiration_date":"2026-04-15","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001213900-25-028232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000121390025028232/ownership.xml","form_type":"4"}},{"id":1186271,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-01T22:07:08.000Z","date":"2024-07-22","kind":"grant","planned":false,"acquired":true,"shares":1875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The share amount has been adjusted to reflect the reverse stock split effective on February 7, 2025 whereby every sixteen shares issued and outstanding prior to the split were combined and converted into one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Reporting Person was granted an option to purchase 1,875 shares of common stock, which vests as to 50% on each of the first and second anniversaries of the grant date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":1875,"derivative":{"exercise_price":1.2,"expiration_date":"2034-07-22","underlying":"Common Stock","underlying_shares":1875},"source":{"system":"sec-edgar","filing":"0001104659-25-030685","document":"tm2511097-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925030685/tm2511097-5_4seq1.xml","form_type":"4"}},{"id":1186270,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-04-01T22:07:08.000Z","date":"2024-07-22","kind":"grant","planned":false,"acquired":true,"shares":625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"The share amount has been adjusted to reflect the reverse stock split effective on February 7, 2025 whereby every sixteen shares issued and outstanding prior to the split were combined and converted into one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest and settle as to 100% of the total number of RSUs on the first anniversary of the grant date, subject to the Reporting Person's continuous employment with the Issuer through such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs will vest and settle as to 100% of the total number of RSUs on the first anniversary of the grant date, subject to the Reporting Person's continuous employment with the Issuer through such date."}],"balance_after":625,"derivative":{"underlying":"Common Stock","underlying_shares":625},"source":{"system":"sec-edgar","filing":"0001104659-25-030685","document":"tm2511097-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925030685/tm2511097-5_4seq1.xml","form_type":"4"}},{"id":1203571,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-17T22:38:10.000Z","date":"2025-03-15","kind":"exercise","planned":false,"acquired":false,"shares":34,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":387,"derivative":{"underlying":"Common Stock","underlying_shares":34},"source":{"system":"sec-edgar","filing":"0001104659-25-024534","document":"tm259558-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925024534/tm259558-4_4seq1.xml","form_type":"4"}},{"id":1203570,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-17T22:38:10.000Z","date":"2025-03-14","kind":"exercise","planned":false,"acquired":false,"shares":31,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":229,"derivative":{"underlying":"Common Stock","underlying_shares":31},"source":{"system":"sec-edgar","filing":"0001104659-25-024534","document":"tm259558-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925024534/tm259558-4_4seq1.xml","form_type":"4"}},{"id":1203569,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-17T22:38:10.000Z","date":"2025-03-15","kind":"exercise","planned":false,"acquired":true,"shares":34,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":1373,"source":{"system":"sec-edgar","filing":"0001104659-25-024534","document":"tm259558-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925024534/tm259558-4_4seq1.xml","form_type":"4"}},{"id":1203568,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-17T22:38:10.000Z","date":"2025-03-14","kind":"exercise","planned":false,"acquired":true,"shares":31,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":1339,"source":{"system":"sec-edgar","filing":"0001104659-25-024534","document":"tm259558-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925024534/tm259558-4_4seq1.xml","form_type":"4"}},{"id":1305043,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-11T01:00:12.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":270000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 7, 2025, the Reporting Person was granted an option to purchase 270,000 shares of common stock, which vests in twelve equal monthly installments over a twelve-month period following the grant date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":270000,"derivative":{"exercise_price":0.4713,"expiration_date":"2035-01-07","underlying":"Common Stock","underlying_shares":270000},"source":{"system":"sec-edgar","filing":"0001104659-25-002689","document":"tm252892-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465925002689/tm252892-3_4seq1.xml","form_type":"4"}},{"id":1328413,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-12-17T23:06:11.000Z","date":"2024-12-15","kind":"exercise","planned":true,"acquired":false,"shares":562,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":5064,"derivative":{"underlying":"Common Stock","underlying_shares":562},"source":{"system":"sec-edgar","filing":"0001104659-24-129461","document":"tm2431371-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465924129461/tm2431371-3_4seq1.xml","form_type":"4"}},{"id":1328412,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-12-17T23:06:11.000Z","date":"2024-12-14","kind":"exercise","planned":true,"acquired":false,"shares":521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":2606,"derivative":{"underlying":"Common Stock","underlying_shares":521},"source":{"system":"sec-edgar","filing":"0001104659-24-129461","document":"tm2431371-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465924129461/tm2431371-3_4seq1.xml","form_type":"4"}},{"id":1328411,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-12-17T23:06:11.000Z","date":"2024-12-16","kind":"sale","planned":true,"acquired":false,"shares":372,"price":0.358,"value":133.176,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023."}],"balance_after":20932,"source":{"system":"sec-edgar","filing":"0001104659-24-129461","document":"tm2431371-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465924129461/tm2431371-3_4seq1.xml","form_type":"4"}},{"id":1328410,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-12-17T23:06:11.000Z","date":"2024-12-16","kind":"sale","planned":true,"acquired":false,"shares":205,"price":0.36,"value":73.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023."}],"balance_after":21157,"source":{"system":"sec-edgar","filing":"0001104659-24-129461","document":"tm2431371-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465924129461/tm2431371-3_4seq1.xml","form_type":"4"}},{"id":1328409,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-12-17T23:06:11.000Z","date":"2024-12-15","kind":"exercise","planned":true,"acquired":true,"shares":562,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":21362,"source":{"system":"sec-edgar","filing":"0001104659-24-129461","document":"tm2431371-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465924129461/tm2431371-3_4seq1.xml","form_type":"4"}},{"id":1328408,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-12-17T23:06:11.000Z","date":"2024-12-14","kind":"exercise","planned":true,"acquired":true,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":20800,"source":{"system":"sec-edgar","filing":"0001104659-24-129461","document":"tm2431371-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465924129461/tm2431371-3_4seq1.xml","form_type":"4"}},{"id":1391730,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-10-04T01:54:22.000Z","date":"2024-10-03","kind":"sale","planned":true,"acquired":false,"shares":7175,"price":0.55,"value":3946.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $0.5500 to $0.5515. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":20279,"source":{"system":"sec-edgar","filing":"0001104659-24-106061","document":"tm2425607-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465924106061/tm2425607-2_4seq1.xml","form_type":"4"}},{"id":1391729,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-10-04T01:54:22.000Z","date":"2024-09-17","kind":"grant","planned":true,"acquired":true,"shares":21250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer previously granted the Reporting Person an award of restricted stock units that would vest based on the Issuer's satisfaction of certain performance objectives and subject to the Reporting Person's continued service with the Issuer through October 1, 2024 (the \"PSUs\"). On September 17, 2024, the Compensation Committee of the Issuer's Board of Directors determined that performance conditions with respect to 21,250 PSUs had been satisfied and 21,250 shares of common stock became issuable to the Reporting Person on October 1, 2024."}],"balance_after":27454,"source":{"system":"sec-edgar","filing":"0001104659-24-106061","document":"tm2425607-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465924106061/tm2425607-2_4seq1.xml","form_type":"4"}},{"id":1404936,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-09-17T23:21:10.000Z","date":"2024-09-15","kind":"exercise","planned":true,"acquired":false,"shares":563,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":5625,"derivative":{"underlying":"Common Stock","underlying_shares":563},"source":{"system":"sec-edgar","filing":"0001104659-24-100749","document":"tm2424255-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465924100749/tm2424255-3_4seq1.xml","form_type":"4"}},{"id":1404935,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-09-17T23:21:10.000Z","date":"2024-09-14","kind":"exercise","planned":true,"acquired":false,"shares":521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":3127,"derivative":{"underlying":"Common Stock","underlying_shares":521},"source":{"system":"sec-edgar","filing":"0001104659-24-100749","document":"tm2424255-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465924100749/tm2424255-3_4seq1.xml","form_type":"4"}},{"id":1404934,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-17T23:21:10.000Z","date":"2024-09-16","kind":"sale","planned":true,"acquired":false,"shares":356,"price":0.6899,"value":245.6044,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023."}],"balance_after":6204,"source":{"system":"sec-edgar","filing":"0001104659-24-100749","document":"tm2424255-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465924100749/tm2424255-3_4seq1.xml","form_type":"4"}},{"id":1404933,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-17T23:21:10.000Z","date":"2024-09-15","kind":"exercise","planned":true,"acquired":true,"shares":563,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6560,"source":{"system":"sec-edgar","filing":"0001104659-24-100749","document":"tm2424255-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465924100749/tm2424255-3_4seq1.xml","form_type":"4"}},{"id":1404932,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-17T23:21:10.000Z","date":"2024-09-14","kind":"exercise","planned":true,"acquired":true,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":5997,"source":{"system":"sec-edgar","filing":"0001104659-24-100749","document":"tm2424255-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465924100749/tm2424255-3_4seq1.xml","form_type":"4"}},{"id":1465740,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-01T20:00:11.000Z","date":"2024-06-27","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest on a quarterly basis over 12 months following June 27, 2024, subject to the Reporting Person's continued service through each applicable vesting date. The options were issued at approximately 9:30 a.m. (ET) on June 27, 2024 with an exercise price of $1.05, representing the most recently reported closing stock price on June 26, 2024."}],"balance_after":125000,"derivative":{"exercise_price":1.05,"expiration_date":"2034-06-27","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0000950170-24-079563","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000095017024079563/ownership.xml","form_type":"4"}},{"id":1475043,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-06-19T01:26:13.000Z","date":"2024-06-15","kind":"exercise","planned":true,"acquired":false,"shares":562,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":6188,"derivative":{"underlying":"Common Stock","underlying_shares":562},"source":{"system":"sec-edgar","filing":"0001104659-24-073002","document":"tm2417544-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465924073002/tm2417544-5_4seq1.xml","form_type":"4"}},{"id":1475042,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-06-19T01:26:13.000Z","date":"2024-06-14","kind":"exercise","planned":true,"acquired":false,"shares":521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":3648,"derivative":{"underlying":"Common Stock","underlying_shares":521},"source":{"system":"sec-edgar","filing":"0001104659-24-073002","document":"tm2417544-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465924073002/tm2417544-5_4seq1.xml","form_type":"4"}},{"id":1475041,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-06-19T01:26:13.000Z","date":"2024-06-17","kind":"sale","planned":true,"acquired":false,"shares":372,"price":1.2622,"value":469.5384,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023."}],"balance_after":5476,"source":{"system":"sec-edgar","filing":"0001104659-24-073002","document":"tm2417544-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465924073002/tm2417544-5_4seq1.xml","form_type":"4"}},{"id":1475040,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-06-19T01:26:13.000Z","date":"2024-06-15","kind":"exercise","planned":true,"acquired":true,"shares":562,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":5848,"source":{"system":"sec-edgar","filing":"0001104659-24-073002","document":"tm2417544-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465924073002/tm2417544-5_4seq1.xml","form_type":"4"}},{"id":1475039,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-06-19T01:26:13.000Z","date":"2024-06-14","kind":"exercise","planned":true,"acquired":true,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":5286,"source":{"system":"sec-edgar","filing":"0001104659-24-073002","document":"tm2417544-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465924073002/tm2417544-5_4seq1.xml","form_type":"4"}},{"id":1545375,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-04-08T23:32:03.000Z","date":"2024-03-15","kind":"exercise","planned":true,"acquired":false,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 15, 2023, the Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":6750,"derivative":{"underlying":"Common Stock","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001104659-24-044860","document":"tm2411220-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465924044860/tm2411220-4_4seq1.xml","form_type":"4"}},{"id":1545374,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-04-08T23:32:03.000Z","date":"2024-03-14","kind":"exercise","planned":true,"acquired":false,"shares":521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":4169,"derivative":{"underlying":"Common Stock","underlying_shares":521},"source":{"system":"sec-edgar","filing":"0001104659-24-044860","document":"tm2411220-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465924044860/tm2411220-4_4seq1.xml","form_type":"4"}},{"id":1545373,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-04-08T23:32:03.000Z","date":"2024-04-04","kind":"sale","planned":true,"acquired":false,"shares":1069,"price":2.635,"value":2816.815,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $2.62 to $2.665. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":4765,"source":{"system":"sec-edgar","filing":"0001104659-24-044860","document":"tm2411220-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465924044860/tm2411220-4_4seq1.xml","form_type":"4"}},{"id":1545372,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-04-08T23:32:03.000Z","date":"2024-03-15","kind":"exercise","planned":true,"acquired":true,"shares":2250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":5834,"source":{"system":"sec-edgar","filing":"0001104659-24-044860","document":"tm2411220-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465924044860/tm2411220-4_4seq1.xml","form_type":"4"}},{"id":1545371,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-04-08T23:32:03.000Z","date":"2024-03-14","kind":"exercise","planned":true,"acquired":true,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":3584,"source":{"system":"sec-edgar","filing":"0001104659-24-044860","document":"tm2411220-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465924044860/tm2411220-4_4seq1.xml","form_type":"4"}},{"id":1697855,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-29T22:23:38.000Z","date":"2023-12-28","kind":"grant","planned":false,"acquired":true,"shares":70311,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This price represents the closing price of the Issuer's common stock on December 28, 2023, the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Issuer's 2019 Stock Plan, 2% of the options will vest each month from the date of grant until fully vested."}],"balance_after":70311,"derivative":{"exercise_price":5,"expiration_date":"2033-12-28","underlying":"Common Stock","underlying_shares":70311},"source":{"system":"sec-edgar","filing":"0001213900-23-100086","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000121390023100086/ownership.xml","form_type":"4"}},{"id":1706949,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-12-18T21:52:59.000Z","date":"2023-12-14","kind":"exercise","planned":false,"acquired":false,"shares":521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":4690,"derivative":{"underlying":"Common Stock","underlying_shares":521},"source":{"system":"sec-edgar","filing":"0001104659-23-126921","document":"tm2333119-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465923126921/tm2333119-2_4seq1.xml","form_type":"4"}},{"id":1706948,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-12-18T21:52:59.000Z","date":"2023-12-14","kind":"exercise","planned":false,"acquired":true,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":3063,"source":{"system":"sec-edgar","filing":"0001104659-23-126921","document":"tm2333119-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465923126921/tm2333119-2_4seq1.xml","form_type":"4"}},{"id":1778763,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-09-18T20:49:10.000Z","date":"2023-09-14","kind":"exercise","planned":false,"acquired":false,"shares":521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":5211,"derivative":{"underlying":"Common Stock","underlying_shares":521},"source":{"system":"sec-edgar","filing":"0001104659-23-101640","document":"tm2326350-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465923101640/tm2326350-5_4seq1.xml","form_type":"4"}},{"id":1778762,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-09-18T20:49:10.000Z","date":"2023-09-14","kind":"exercise","planned":false,"acquired":true,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":2542,"source":{"system":"sec-edgar","filing":"0001104659-23-101640","document":"tm2326350-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465923101640/tm2326350-5_4seq1.xml","form_type":"4"}},{"id":1851871,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-06-16T22:42:00.000Z","date":"2023-06-14","kind":"exercise","planned":false,"acquired":false,"shares":521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":5732,"derivative":{"underlying":"Common Stock","underlying_shares":521},"source":{"system":"sec-edgar","filing":"0001104659-23-072397","document":"tm2319006-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465923072397/tm2319006-3_4seq1.xml","form_type":"4"}},{"id":1851870,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-16T22:42:00.000Z","date":"2023-06-14","kind":"exercise","planned":false,"acquired":true,"shares":521,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":2021,"source":{"system":"sec-edgar","filing":"0001104659-23-072397","document":"tm2319006-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465923072397/tm2319006-3_4seq1.xml","form_type":"4"}},{"id":1891307,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-05-17T00:32:19.000Z","date":"2023-05-14","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On May 14, 2022, the Reporting Person was granted 5,000 RSUs that vested and settled on May 14, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On May 14, 2022, the Reporting Person was granted 5,000 RSUs that vested and settled on May 14, 2023."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001104659-23-061538","document":"tm2316022-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465923061538/tm2316022-2_4seq1.xml","form_type":"4"}},{"id":1891306,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-17T00:32:19.000Z","date":"2023-05-15","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":27.1727,"value":135863.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 23, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $26.84 to $27.63. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":1500,"source":{"system":"sec-edgar","filing":"0001104659-23-061538","document":"tm2316022-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465923061538/tm2316022-2_4seq1.xml","form_type":"4"}},{"id":1891305,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-17T00:32:19.000Z","date":"2023-05-14","kind":"exercise","planned":true,"acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":6500,"source":{"system":"sec-edgar","filing":"0001104659-23-061538","document":"tm2316022-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465923061538/tm2316022-2_4seq1.xml","form_type":"4"}},{"id":1902691,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-05-05T23:35:42.000Z","date":"2023-05-04","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest on a quarterly basis over the next 12 months.  The options were issued at approximately 9:50 a.m. (ET) on May 4, 2023, with an exercise price of $0.662, representing the most recently reported closing stock price on May 3, 2023."}],"balance_after":125000,"derivative":{"exercise_price":0.662,"expiration_date":"2033-05-04","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001437749-23-012870","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923012870/rdgdoc.xml","form_type":"4"}},{"id":1949871,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-16T22:02:03.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of March 15, 2023 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":32000,"derivative":{"exercise_price":19.6,"expiration_date":"2033-03-15","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001104659-23-033408","document":"tm239796-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465923033408/tm239796-6_4seq1.xml","form_type":"4"}},{"id":1949870,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-16T22:02:03.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":9000,"derivative":{"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001104659-23-033408","document":"tm239796-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465923033408/tm239796-6_4seq1.xml","form_type":"4"}},{"id":1949869,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-16T22:02:03.000Z","date":"2023-03-14","kind":"exercise","acquired":false,"shares":2084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":6253,"derivative":{"underlying":"Common Stock","underlying_shares":2084},"source":{"system":"sec-edgar","filing":"0001104659-23-033408","document":"tm239796-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465923033408/tm239796-6_4seq1.xml","form_type":"4"}},{"id":1949868,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-16T22:02:03.000Z","date":"2023-03-15","kind":"sale","acquired":false,"shares":2084,"price":19.5,"value":40638.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 23, 2022."}],"balance_after":1500,"source":{"system":"sec-edgar","filing":"0001104659-23-033408","document":"tm239796-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465923033408/tm239796-6_4seq1.xml","form_type":"4"}},{"id":1949867,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-16T22:02:03.000Z","date":"2023-03-14","kind":"exercise","acquired":true,"shares":2084,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":3584,"source":{"system":"sec-edgar","filing":"0001104659-23-033408","document":"tm239796-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465923033408/tm239796-6_4seq1.xml","form_type":"4"}},{"id":2217025,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-01T23:16:03.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":72156,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This price represents the closing price of the Company's common stock on July 1, 2022, the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Company's 2019 Stock Plan, 2% of the options will vest each month from July 1, 2022 until fully vested."}],"balance_after":72156,"derivative":{"exercise_price":4.96,"expiration_date":"2032-07-01","underlying":"Common Stock","underlying_shares":72156},"source":{"system":"sec-edgar","filing":"0001213900-22-036873","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000121390022036873/ownership.xml","form_type":"4"}},{"id":2267755,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP and CFO"}}],"security":"Restricted Stock Units","published_at":"2022-05-17T19:40:21.000Z","date":"2022-05-14","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest and settle on May 14, 2023, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest and settle on May 14, 2023, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest and settle on May 14, 2023, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":5000,"derivative":{"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001104659-22-061919","document":"tm2215808-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465922061919/tm2215808-2_4seq1.xml","form_type":"4"}},{"id":2270260,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2022-05-16T22:20:16.000Z","date":"2022-05-13","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest on a quarterly basis over the next 12 months. Option grant was issued at 9:30 a.m. (ET) on May 13, 2022, with an exercise price of $0.93, representing the most recently reported closing stock price on May 12, 2022."}],"balance_after":500000,"derivative":{"exercise_price":0.93,"expiration_date":"2032-05-13","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001437749-22-012710","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774922012710/rdgdoc.xml","form_type":"4"}},{"id":2330511,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-16T20:16:29.000Z","date":"2022-03-14","kind":"grant","acquired":true,"shares":33350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of March 14, 2022 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":33350,"derivative":{"exercise_price":15.31,"expiration_date":"2032-03-14","underlying":"Common Stock","underlying_shares":33350},"source":{"system":"sec-edgar","filing":"0001104659-22-034488","document":"tm229449-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465922034488/tm229449-2_4seq1.xml","form_type":"4"}},{"id":2330510,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-03-16T20:16:29.000Z","date":"2022-03-14","kind":"grant","acquired":true,"shares":8337,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":8337,"derivative":{"underlying":"Common Stock","underlying_shares":8337},"source":{"system":"sec-edgar","filing":"0001104659-22-034488","document":"tm229449-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465922034488/tm229449-2_4seq1.xml","form_type":"4"}},{"id":2578914,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-03T21:02:21.000Z","date":"2021-09-01","kind":"grant","acquired":true,"shares":18351,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from September 1, 2021 until fully vested."}],"balance_after":18351,"derivative":{"exercise_price":6.07,"expiration_date":"2031-09-01","underlying":"Common Stock","underlying_shares":18351},"source":{"system":"sec-edgar","filing":"0001213900-21-046683","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000121390021046683/ownership.xml","form_type":"4"}},{"id":2708032,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2021-05-18T20:16:30.000Z","date":"2021-05-14","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest on a quarterly basis over the next 12 months. Option grant was issued at 4:30 p.m. (ET) on May 14, 2020 with an exercise price of $2.90, representing the most recently reported closing stock price at the time of grant."}],"balance_after":50000,"derivative":{"exercise_price":2.9,"expiration_date":"2031-05-14","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001437749-21-012672","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774921012672/rdgdoc.xml","form_type":"4"}},{"id":2769180,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-30T00:45:46.000Z","date":"2021-03-25","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of March 25, 2021 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":20000,"derivative":{"exercise_price":41.17,"expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-21-043484","document":"tm217124-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465921043484/tm217124-12_4seq1.xml","form_type":"4"}},{"id":2881339,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2021-02-03T21:15:58.000Z","date":"2021-02-01","kind":"exercise","acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this stock option vested and became exercisable as to 21,093 shares on October 1, 2018, and the remaining 62,805 shares have vested or will vest monthly over 36 months from October 2, 2018 through October 1, 2021."}],"balance_after":80148,"derivative":{"exercise_price":5.55,"expiration_date":"2027-10-02","underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001104659-21-011542","document":"tm215213-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465921011542/tm215213-1_4seq1.xml","form_type":"4"}},{"id":2881338,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-03T21:15:58.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":3750,"price":48.15,"value":180562.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.00 to $48.73. The reporting person undertakes to provide BioXcel Therapeutics, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1500,"source":{"system":"sec-edgar","filing":"0001104659-21-011542","document":"tm215213-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465921011542/tm215213-1_4seq1.xml","form_type":"4"}},{"id":2881337,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-03T21:15:58.000Z","date":"2021-02-01","kind":"exercise","acquired":true,"shares":3750,"price":5.55,"value":20812.5,"ownership":{"direct":true},"balance_after":5250,"source":{"system":"sec-edgar","filing":"0001104659-21-011542","document":"tm215213-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465921011542/tm215213-1_4seq1.xml","form_type":"4"}},{"id":3057138,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-14T21:03:50.000Z","date":"2020-08-12","kind":"grant","acquired":true,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from August 12, 2020 until fully vested."}],"balance_after":8333,"derivative":{"exercise_price":9.55,"expiration_date":"2030-08-12","underlying":"Common Stock","underlying_shares":8333},"source":{"system":"sec-edgar","filing":"0001213900-20-022320","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000121390020022320/ownership.xml","form_type":"4"}},{"id":3131976,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":10174,"kind":"person","name":"Steinhart Richard I","position":1,"cik":"0001293789","reported_name":"Steinhart Richard I","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-05-28T20:16:00.000Z","date":"2020-05-26","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of May 26, 2020 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":55000,"derivative":{"exercise_price":45.99,"expiration_date":"2030-05-25","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001104659-20-067056","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293789/000110465920067056/a4.xml","form_type":"4"}}],"next_cursor":"2020-05-28T20:16:00.000000Z,3131976"}